VRX (Valeant Pharmaceuticals), BULLISH TECHNICALS & RATINGSOn a
daily chart, VRX (Valeant Pharmaceuticals) is hugely bullish and staging a full comeback. Note that VRX and VRX.TO mimic each other on charts, so US-based analyst recommendation has direct impact on Canadian TSX listed VRX.TO.
Here BULLISH signs generated after closing today: 1. Parabolic SAR (Stop and Reverse) has finally generated a BUY signal today (after so long!);
2. MACD cross-over is pointing up and indicating that bearish sentiment is nearing it's end;
3. Finaly, the price broke
20-day Simple Moving Average and is not siting on it indicating bulls are taking over.
4. ADX Line is trending with DMI+ and DMI- contracting, indicating that bears (sellers) are losing ground and bulls (buyers) are taking over; we expect DMI+ and DMI- crossover, with bulls taking over.
PLUS - major US insitutional trading firms are recommending BUY on VRX Valeant Pharmaceuticals with price targets ranging
from 20% to 50% GAIN from today's closing price:
11/20/2015 – Valeant Pharmaceuticals Intl (VRX) had its price target set at US$111 by analysts at Mizuho. They now have a “BUY” rating on the stock.
11/19/2015 – Valeant Pharmaceuticals Intl had its “BUY” rating reaffirmed by analysts at Canaccord Genuity. They now have a US$170.00 price target on the stock.
11/19/2015 – Valeant Pharmaceuticals Intl is now covered by analysts at Citigroup Inc. They set an “overweight” rating on the stock with a "BUY" recomendation.
11/17/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at Morgan Stanley to US$98.00. They now have an “equal weight” rating on the stock and recommend a "BUY."
11/12/2015 – Valeant Pharmaceuticals Intl had its “BUY” rating reaffirmed by analysts at Bank of America.
11/12/2015 – Valeant Pharmaceuticals Intl had its “HOLD” rating reaffirmed by analysts at Deutsche Bank.
11/11/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at TD Securities to US$160.00. They now have a “BUY” rating on the stock.
11/11/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at RBC Capital to US$206.00. They now have an “OUTPERFORM” rating on the stock.
11/11/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at Stifel Nicolaus to US$200.00. They now have a “BUY” rating on the stock.
11/11/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at JPMorgan Chase & Co. to US$225.00. They now have an “OVERWEIGHT” rating on the stock.
11/11/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at Nomura to US$175.00. They now have a “BUY” rating on the stock.
11/6/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at Guggenheim to US$195.00. They now have a “buy” rating on the stock.
11/5/2015 – Valeant Pharmaceuticals Intl had its “BUY” rating reaffirmed by analysts at Mizuho.
11/3/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at Deutsche Bank to US$136.00. They now have a “HOLD” rating on the stock.
11/3/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at RBC Capital to US$213.00. They now have an “outperform” rating on the stock.
11/3/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at BMO Capital Markets to US$133.00. They now have a “MARKET PERFORM” rating on the stock.
11/2/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at Scotiabank to US$170.00.
11/2/2015 – Valeant Pharmaceuticals Intl had its price target set by analysts at Jefferies Group to US$172.00. They now have a “BUY” rating on the stock.
11/2/2015 – Valeant Pharmaceuticals Intl had its “BUY” rating reaffirmed by analysts at Canaccord Genuity. They now have a US$170.00 price target on the stock.
11/2/2015 – Valeant Pharmaceuticals Intl was target price was set by analysts at Goldman Sachs to US$122.00 price target on the stock.
11/1/2015 – Valeant Pharmaceuticals Intl had its “BUY” rating reaffirmed by analysts at Bank of America. They now have a US$173.00 price target on the stock.
11/1/2015 – Valeant Pharmaceuticals Intl had its "EQUAL WEIGHT” rating reaffirmed by analysts at Morgan Stanley.
11/1/2015 – Valeant Pharmaceuticals Intl had its “BUY” rating reaffirmed by analysts at Stifel Nicolaus. They now have a US$285.00 price target on the stock.
Short-sellers will get burned really hard and will eventually need to cover their positions which will end in a short-squeeze and help the bulls catapult a huge comeback in stock price.